Experimental Procedures. No Seller has performed or authorized the performance of any experimental or research procedures or studies involving patients of any Facility that require the prior approval of any governmental entity that has not been obtained.
Experimental Procedures. During the past five (5) years Seller has not performed or permitted the performance of any Experimental Procedures involving patients in the Healthcare Facilities not authorized and conducted in accordance with the procedures of the applicable Institutional Review Board.
Experimental Procedures. Sellers have not performed or permitted the performance of any experimental or research procedures or studies involving patients of the Hospital not authorized and conducted in accordance with applicable law and the procedures of the Institutional Review Board of the Hospital.
Experimental Procedures. The Seller Entities have not performed or permitted the performance of any experimental or research procedures or studies involving patients of any Hospital not authorized and conducted in accordance with the procedures of the Institutional Review Board of the relevant Hospital
Experimental Procedures. The Seller Entities have not performed or permitted the performance of any experimental or research procedures or studies involving patients of the Hospital not authorized and conducted in accordance with the procedures of the Institutional Review Board of the Hospital. All human subject research (as that phrase is defined by federal Law), or research governed by the federal Animal Welfare Act, involving the Seller Entities is identified on Schedule 3.23.
Experimental Procedures. The study protocol was approved by the University of California, Berkeley Committee for Protection of Human Subjects, following the declaration of Helsinki. All partici- pants gave written informed consent after the nature of Patient Lesion volume (cm3) % STG and MTG % AG and SMG % LIFG P1 18.32 26.9 7.4 0 P2 4.51 5.6 0 0 P3 93.75 62.3 48 0 P4 36.95 45.5 0 0 P5 103.17 22.7 21.7 21.4 P6 85.82 84.5 43.1 0 Mean (sd) 57.08 (38.68) 41.25 (28.82) 20 (21.4) 3.57 (8.74)
Experimental Procedures. During the past three (3) years, Seller has not performed nor permitted the performance of any experimental or research procedures or studies involving patients in the Hospital except, in all material respects, to the extent authorized by and conducted in accordance with the procedures of an Institutional Review Board responsible for oversight of research at the Hospital.
Experimental Procedures. 2.2.1. Materials
Experimental Procedures. Animals Erythrocyte parameters
Experimental Procedures. Construction of plant expression vector pRF-VP16 Plant expression vector pGPTV-KAN (Xxxxxx et al., 1992) was modified in order to obtain pRF-VP16. Briefly, NotI and SfiI sites within the vector backbone were removed via sequential digestion and treatment with Klenow enzyme and T4 DNA polymerase, respectively. These modifications did not hamper the frequency of plant transformation. The promoterless XXX coding sequence was replaced by a 1.7 kb XmaI–SacI fragment containing the RPS5A promoter (Xxxxxxx et al., 2001), after which the plasmid was digested with SacI followed by insertion of a sequence providing the vector with an ATG translational start codon, a FLAG tag, a SV40 nuclear localization signal and NotI and XhoI sites. An XhoI–SacI fragment encoding the 37 C-terminal amino acids of the VirF protein of an octopine strain of Agrobacterium tumefaciens was added to the vector. Although this domain was of no further specific relevance for this study, the DNA fragment provided a translational stop codon for the fusion proteins produced in planta. The unique NotI site was used for introduction of the VP16 transcriptional activation domain (Xxxxxxxx et al., 1988), and SfiI sites were used for directional cloning of zinc finger domains. The most relevant features of the resulting plant expression plasmid pRF-VP16 are shown in Figure 1(b). The plasmid sequence is available upon request. Construction of 3ZF-ATF pools Zinc finger modules designed for 5'-GNN-3' or 5'-(GNN)2-3' binding sites were constructed in pSKN-SgrAI as described previously (Neuteboom et al., 2006), using annealed oligonucleotide pairs each encoding an optimal zinc finger sequence as established by Xxxxx et al. (1999). Once a sequence-verified series of constructs encoding two-finger (2F) proteins sharing the C-terminal finger was established, the third finger was added in a controlled manner (Figure 1a). For each 2F series, the sixteen 2F constructs were grown overnight in LC medium containing carbenicillin at 100 mg/l for plasmid selection, and glucose (20 mm) in order to repress any untimely expression of the ZF proteins via the lac promoter. A larger volume (100 ml) of the same medium was subsequently inoculated with equal amounts of each of the 16 bacterial strains belonging to the series (corresponding to 0.5 ml of bacterial culture with an OD of 1.0 at 600 nm) and grown for an additional 4 h. Plasmid DNA was isolated, digested with SgrAI, and subdivided for 16 separate ligation reactio...
